Heron Pharmaceutical key facts
as of Oct 2026- Developer and provider of pharmaceutical R&D services and specialty drug development solutions designed for the discovery and optimization of innovative, modified, and generic medicines.
- Heron Pharmaceutical is valued at approximately $377.9M as of Oct 2026 (last reported valuation).
- It has raised $46.2M; the latest was Later Stage VC ($19.8M) in Dec 2025.
- Notable investors include DPH Capital, Guosheng Capital, SUNNOVO, Tibet Dorui Pharmaceutical, Xi'an Manareco.
- Status: Privately Held (backing).
Heron Pharmaceutical's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·Watch Heron Pharmaceutical: the Monday email on marks, rounds and moves
Heron Pharmaceutical funding rounds
No funding rounds for Heron Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Heron Pharmaceutical
5Heron Pharmaceutical valuation
Heron Pharmaceutical's last reported valuation was $378 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Heron Pharmaceutical investors
5 investors are on record for Heron Pharmaceutical, including DPH Capital, Guosheng Capital, SUNNOVO and Tibet Dorui Pharmaceutical.
About Heron Pharmaceutical
Developer and provider of pharmaceutical R&D services and specialty drug development solutions designed for the discovery and optimization of innovative, modified, and generic medicines. The company provides integrated preclinical development services-including API and formulation process development, quality and stability studies-as well as technology transfer and consulting, enabling biopharma clients to accelerate drug development and regulatory readiness.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2013
- Employees
- 344
- Website
- heronpharma.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.